A polypill containing three recommended heart failure therapies improved heart function, reduced hospitalizations and was ...

HOUSTON -- A novel self-administered shot that inhibits two key immunoregulatory cytokines reduced proteinuria in patients with IgA nephropathy, interim findings from the phase III ORIGIN 3 trial ...

Cancer treatments can exert cardiotoxic effects, but screening and monitoring can detect and minimize cancer therapy-related ...

The results of high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at American Society of Nephrology Kidney Week 2025 November 5–9.

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with ...

The benefits are observed across patient subtypes and potentially offer the chance to avoid dialysis and implement a new standard of care.

A rapid multidisciplinary approach is needed to reduce serum free light chain levels and restore kidney function ...

Given the success of atacicept in phase 2 trials, investigators tested the dual inhibitor of BAFF and APRIL in patients with IgA nephropathy in the phase 3 ORIGIN trial.

The report further notes that structural abnormalities in the GBM, as seen in Alport syndrome, may predispose patients to ...

Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.